Metacrine Inc

NASDAQ:MTCR   11:23:38 AM EDT
1.70
-2.13 (-55.61%)
Regulatory, Earnings Announcements

Metacrine, Inc. Reports Positive Results From Phase 1 Trial Of Met642

Published: 12/17/2020 11:40 GMT
Metacrine Inc (MTCR) - Metacrine, Inc. - Reports Positive Results From Phase 1 Trial of Met642.
Metacrine, Inc. - Doses Selected for Phase 2a Trial in Patients With Nash; On-track to Initiate in 1h21 for Met642 Trial.
Metacrine, Inc. - Treatment With Met642 in Trial Was Safe and Generally Well-tolerated and Demonstrated a Sustained Pharmacokinetic Profile.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.